Influence of age, past smoking, and disease severity on tlr2, neutrophilic inflammation, and MMP-9 Levels in COPD by Simpson, JL et al.
Hindawi Publishing Corporation
Mediators of Inflammation
Volume 2013, Article ID 462934, 13 pages
http://dx.doi.org/10.1155/2013/462934
Clinical Study
Influence of Age, Past Smoking, and Disease Severity on TLR2,
Neutrophilic Inflammation, and MMP-9 Levels in COPD
Jodie L. Simpson,1,2,3 Vanessa M. McDonald,1,2,3,4 Katherine J. Baines,1,2,3
Kevin M. Oreo,1,2,3 Fang Wang,5 Philip M. Hansbro,3 and Peter G. Gibson1,2,3
1 NHMRC Centre for Respiratory and Sleep Medicine, Faculty of Health, School of Medicine and Public Health,
The University of Newcastle, Callaghan, NSW 2308, Australia
2 Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, NSW 2305, Australia
3 Priority Research Centre for Asthma and Respiratory Diseases and Hunter Medical Research Institute, The University of Newcastle,
Callaghan, NSW 2308, Australia
4 School of Nursing and Midwifery, The University of Newcastle, Callaghan, NSW 2308, Australia
5 Norman Bethune Medical College, Ji Lin University, Changchun 130021, China
Correspondence should be addressed to Jodie L. Simpson; jodie.simpson@hnehealth.nsw.gov.au
Received 8 January 2013; Revised 21 February 2013; Accepted 21 February 2013
Academic Editor: Helen C. Steel
Copyright © 2013 Jodie L. Simpson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Chronic obstructive pulmonary disease (COPD) is a common and serious respiratory disease, particularly in older individuals,
characterised by fixed airway obstruction and persistent airway neutrophilia. The mechanisms that lead to these features are not
well established.We investigated the contribution of age, prior smoking, and fixed airflow obstruction on sputumneutrophils, TLR2
expression, and markers of neutrophilic inflammation. Induced sputum from adults with COPD (𝑛 = 69) and healthy controls
(𝑛 = 51) was examined. A sputum portion was dispersed, total, differential cell count and viability recorded, and supernatant
assayed for CXCL8, matrix metalloproteinase- (MMP-) 9, neutrophil elastase, and soluble TLR2. Peripheral blood cells (𝑛 = 7)
were stimulated and TLR2 activation examined. TLR2 levels were increased with ageing, while sputum neutrophils and total
sputum MMP-9 levels increased with age, previous smoking, and COPD. In multivariate regression, TLR2 gene expression and
MMP-9 levels were significant independent contributors to the proportion of sputum neutrophils after adjustment for age, prior
smoking, and the presence of airflow obstruction. TLR2 stimulation led to enhanced release of MMP-9 from peripheral blood
granulocytes. TLR2 stimulation activates neutrophils for MMP-9 release. Efforts to understand the mechanisms of TLR2 signalling
and subsequent MMP-9 production in COPD may assist in understanding neutrophilic inflammation in COPD.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a disease
of global significance that is a major contributor to mortality
and morbidity in older people [1]. Cigarette smoking is a
major risk factor, 64 million people are affected worldwide,
and it is the 4th most common cause of death [2]. COPD is
characterized by airflow obstruction that is progressive and
incompletely reversed by current therapy [3]. This under-
scores the need to better understand the diseasemechanisms,
to facilitate the search for new treatment modalities in
COPD [4]. Airway inflammation is a key element of COPD
and typically involves persistent neutrophilic airway inflam-
mation (neutrophilic bronchitis). Neutrophilic bronchitis is
persistent and not reversed after the removal of stimuli such
as tobacco smoke and may contribute to disease progression.
Understanding the mechanisms of persistent neutrophilia is
likely to inform the identification of new therapeutic targets
in COPD.
We previously reported the involvement of the innate
immune system in airway diseases that are characterized by
neutrophilic bronchitis (the neutrophilic subtype of asthma
and bronchiectasis) [5]. TLR2 gene expression is elevated in
patients with COPD [6], and surface expression is reduced
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in airway cells from patients with COPD compared to
controls [7, 8] suggesting a disease-related alteration in TLR2
expression. Ageing is also associatedwith airway neutrophilia
implicating a role for altered innate immune responses in
older individuals. It is not clear if the changes in neutro-
phil accumulation with advancing age are accompanied by
enhanced CXCL8 and neutrophil protease (e.g., NE) release.
Smoking also induces and enhances neutrophil responses.
Nevertheless, the extent to which factors such as age and past
smoking impact on the persistent neutrophilic bronchitis in
COPD is uncertain.
Here we report on our investigations of these issues. We
hypothesized that neutrophilic airway inflammation and
TLR2 expression would increase with age and past smoking,
but would be further unregulated in COPD. We assessed
neutrophilic inflammation and the associated expression of
neutrophil and innate immune mediators whilst controlling
for the effects of age, smoking, and the presence and severity
of airway obstruction. A disease specific dysregulation of
these components may represent potential future targets for
therapy in patients with COPD.
2. Material and Methods
2.1. Ethics Statement. Participants gave written informed
consent. The Hunter New England Area Health Service and
University of Newcastle Research Human Ethics Committees
approved this study.
2.2. Participant Recruitment. We recruited consenting adults
who were greater than 55 years of age with COPD (𝑛 =
100) from a tertiary care setting of the Respiratory and Sleep
Medicine Ambulatory Care Service at John Hunter Hospital,
NSW, Australia. A group of healthy controls (𝑛 = 61, 𝑛 =
22 < 55 years, and 𝑛 = 39 > 55 years, resp.) were recruited
from the community by advertisement. COPD diagnosis
was assessed by a physician and by post-bronchodilator
spirometry. Participants were excluded (𝑛 = 16) if the
results did not meet GOLD criteria of postbronchodilator
FEV
1
/FVC < 70% and FEV
1
< 80% [3].
Participants had no reported exacerbations or alterations
in respiratory medications in the previous four weeks and
were excluded from analysis if they were taking maintenance
oral corticosteroids (𝑛 = 3) or long-term antibiotic therapy
(tetracycline and macrolide, 𝑛 = 2) or had a diagnosis of
COPD secondary to a diagnosis of bronchiectasis (𝑛 = 4).
Further exclusion criteria were current smoking (𝑛 = 6
COPD, 𝑛 = 3 control) or having ceased smoking in the past
6 months (𝑛 = 1 control). Healthy controls had normal lung
function and no diagnosis of airways disease. Healthy con-
trols were excluded if they reported respiratory symptoms in
combination with one or more of either airflow obstruction,
airway inflammation, or airways hyperresponsiveness to
hypertonic saline (𝑛 = 6). The final group for analysis con-
sisted of 69 patients with COPD and 51 healthy controls.
2.3. Design. Participants attended three visits. Pre- and
post-bronchodilator spirometry, symptoms, quality of life,
medication use, smoking status, and exhaled carbon monox-
ide were assessed at visit one, and sputum induction was
undertaken. At visit two, skin allergy tests and a repeat
sputum induction (if required) were performed. On the final
visit a single breath diffusing capacity test was performed.
Sputum was processed for inflammatory cell counts, gene
expression and protein levels of inflammatorymediators, and
bacteria analysis. A group of 7 participants with COPD pro-
vided an additional sample of peripheral blood for isolation
and stimulation of granulocytes and mononuclear cells to
investigate the activation of TLR2 in vitro.
2.4. Quality of Life and Health Care Utilisation. Quality of life
was examined using the SF-36 questionnaire [9].We assessed
health care utilisation by asking participants about their
visits to hospital, emergency room, and General Practitioner,
due to their chest disease. The number of courses of oral
corticosteroids or antibiotics for their disease in the past 12
months was also recorded.
2.5. Mucus Production and Chronic Bronchitis. Mucus pro-
duction was noted as positive if the participant reported an
affirmative answer to the following questions: “Do you cough
and produce sputum/phlegm?”, “Do you usually bring up
phlegm from your chest?”, or “Do you usually have phlegm
in your chest that is difficult to bring up when you don’t
have a cold?”The presence of chronic bronchitis was assessed
using questions taken from the 1978 ATS/DLD Respiratory
Symptom Questionnaire [10].
2.6. Smoking Assessment. A smoking history was taken and
smoking pack-years determined. Participants underwent
exhaled carbonmonoxide (eCO)measurements, determined
by electrochemical detection with a Smokerlyzer (Bedfont,
Kent, UK; detection limit of 1 ppb). All included participants
had an eCOof less than 10 ppm confirming their nonsmoking
status [11].
2.7. Pulmonary Function Tests. Participants withheld bron-
chodilators for their duration of action before testing. Three
reproduciblemeasurements of FEV
1
and forced vital capacity
(FVC) were obtained (KoKo PD Instrumentation, USA)
before and after inhalation of 200𝜇g salbutamol via ametered
dose inhaler with valved holding chamber (Volumatic, Allen
and Hanburys, Australia). These measures were compared
with predicted values according to Knudson et al. [12]. The
carbonmonoxide transfer coefficient (KCO) was determined
according toATS guidelines (MedGraphics Elite DX,Medical
Graphics Corporation, USA) [13].
2.8. Sputum Induction and Analysis. Sputum induction with
hypertonic saline (4.5%) was performed as previously
described [14]. Selected sputum (100 𝜇L) was either stored
in buffer RLT (Qiagen, Hilden, Germany) at −80∘C for RNA
extraction or dispersed using dithiothreitol (DTT). A total
cell count of leukocytes and viability was performed on
filtered suspensions. Following centrifugation, supernatant
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was stored at−80∘C for the assessment of CXCL8, totalMMP-
9, and NE. When sputum volume was <100 𝜇L, a cell smear
was prepared, and total cell count and viability data were
not collected. Cytospins were prepared and stained (May-
Grunwald Giemsa), and a differential cell count was obtained
from 400 nonsquamous cells.
2.9. Sputum Gene Expression. RNA was extracted from
induced sputum samples using RNeasy Mini Kit (Qiagen,
Hilden, Germany) and quantitated using Quant-iT Ribo-
Green RNA Quantitation Assay Kit (Molecular Probes Inc.,
Invitrogen, Eugene, OR, USA).
Gene expression for TLR2, TLR4 was analysed using
quantitative real-time PCR. Sputum RNA (200 ng) was
reverse transcribed to cDNA and combined with TaqMan
primers and probes for TLR2 or TLR4 and the reference
housekeeping gene eukaryotic 18S ribosomal RNA in duplex
real-timePCRs, as previously described (7500Real TimePCR
System, Applied Biosystems, USA) [15]. Relative gene expres-
sion to 18S RNA and an internal calibrator was determined
using the 2−ΔΔCt method.
2.10. Sputum Supernatant Mediator Assessment. Soluble
TLR2, CXCL8, and total MMP-9 were assessed using com-
mercial ELISA kits (R&D Systems, Minneapolis, MN, USA)
and NE was measured with the InnoZyme Human Neu-
trophil Elastase ImmunocaptureActivity Assay (Calbiochem,
Merck, Kilsyth, VIC, Australia).
2.11. Peripheral Blood Isolation and Stimulation. Periph-
eral blood was collected in sodium citrate (18mL), and
granulocytes and mononuclear cell fractions were isolated
using density gradient separation (Percoll GE Healthcare,
Rydalmere, NSW, Australia). Isolated cells were cultured
(1 × 106 cells/mL) in RPMI1640 complete (1% FCS, 0.05%
penicillin/streptomycin), 0.5% HEPES (Invitrogen, Mul-
grave, VIC, Australia) and stimulated with agonists of TLR2
(Pam3CysK4, 1000 ng/mL; TLR2 agonist; EMC Microcol-
lections, Tübingen, Germany). Cell-free supernatants were
collected after 24 hours, and cells were analysed using flow
cytometry or stored in RLT buffer (Qiagen, Doncaster, VIC,
Australia) with 0.01% 𝛽-mercaptoethanol (Sigma-Aldrich,
Castle Hill, NSW, Australia) for assessment of gene expres-
sion. CXCL8, IL-6, IL-1b, TNF-a were measued by flow cyto-
metric bead array (Cytometric Bead Array, BD Biosciences,
USA), with data exported from FACSDiva 5 software and
analysed using FCAP Array Software (BD Pharmingen,
USA). MMP-9 (R&D Systems, USA) and NE (Calbiochem,
USA), were measured using ELISA and analysed on FluoStar
(BMG Labtech, Mornington, VIC, Australia). TLR2 surface
expression was determined by adding cultured cells to an
antibody cocktail (TLR2; eBioscience, San Diego, CA, USA,
and CD16 and CD45: BD Pharmingen, North Ryde, NSW,
Australia) for 30mins, and expression was corrected with
matched isotypes. Cells were then assayed on FACSCanto
II flow cytometer (BD Pharmingen) using BD FACSDiva 5
software. Data were exported from FACSDiva 5 software and
analysed using FCAP Array Software (BD Pharmingen).
2.12. Data Analysis. Data were analysed using Stata 11 (Stata
Corporation, College Station, TX, USA). Results are reported
as mean (SD) or median (q1, q3) unless otherwise indicated.
Analysis was performed using the two-sampleWilcoxon rank
sum test, and the Kruskal-Wallis test was used for more than
two groups. Fisher’s exact test was used for categorical data. In
vitro data were assessed using the Wilcoxon-signed rank test
for paired data. Associations between data were determined
using the Spearman rank correlation. Predictor variables
were included in the multiple linear regressions if 𝑃 < 0.1
in simple linear regression, and known confounders of age
and gender were included in all models. Predicted variables
were tested for colinearity using STATA’s variance inflation
factors postestimation. Flow cytometry relative median fluo-
rescence intensity (RMFI) values were generated by dividing
the MFI of the test antibody with that of the matched
isotope control. All results were reported as significant, when
𝑃 < 0.05.
3. Results
3.1. Study Population. One hundred and twenty adults par-
ticipated in the study, comprising 69 adults with COPD aged
>55 years and 51 healthy controls (29 aged ≥55 years older
healthy controls and 22 aged<55 years of age, younger healthy
controls). Demographic and inflammatory cell count data are
shown in Tables 1 and 2, respectively.
The majority of participants with COPD had moderate
airflow obstruction (𝑛 = 37, 54%), with 26 (38%) severe and
6 (9%) in the very severe category. Use of inhaled corti-
costeroids was common (87%) with a median (q1, q3) dose
of 2000 (1000, 2000) 𝜇g daily, and 57 (83%) were taking
regular long-acting beta-agonists, while 46 (67%)were taking
regular tiotropium bromide. In the 12 months prior to this
study, 77% had visited their GP for their airways disease,
28% had been admitted to hospital, and 48% had received
oral corticosteroids. Induced sputum samples of good quality
were collected from 58 (92%) of participants, and analysis of
cell differential and inflammatory mediators was carried out
using only those participants with adequate sputum samples.
Participants with COPD had an increased number of cells
and cell viability, with increased proportion and number of
neutrophils and eosinophils. There were also significantly
lower proportions of sputum lymphocytes in patients with
COPD compared with healthy controls (Table 2).
3.2. Effect of Age on Neutrophilic Inflammation and Innate
Immune Mediator Expression. To examine the effect of
age we compared younger never-smoking controls with
older never-smoking controls. There was a significant age-
related increase in neutrophilic inflammation identified by
increased sputum neutrophils (Figure 1(a)) and MMP-9
(Figure 1(c)).These increases were accompanied by enhanced
TLR2 gene expression (Figure 1(e)) and soluble TLR2 protein
levels (Figure 1(f)). There were no differences in CXCL8
(Figure 1(d)) or sputum TLR4 gene expression between
younger controls (0.11 (0.0, 0.12)) and older controls (0.13
(0.10, 0.17), 𝑃 = 0.172).
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Table 1: Clinical characteristics for all participants. Data are median (q1, q3) unless indicated.
COPD Older healthy control Younger healthy control 𝑃
𝑛 69 29 22
Age, years mean (SD) 70.0 (7.3) 65.9 (6.8)∗ 32.3 (10.0)∗† <0.001
Sex, 𝑛 (%) males 34 (49) 15 (52) 6 (27) 0.157
Smoker, never/ex 17/52 13/16 20/2∗† <0.001
Pack years 34.8 (18.3, 56.3) 18.5 (2.1, 41.9) 2.9, 4.5 0.056
Years since ceased smoking (exsmokers), mean (SD) 19.8 (13.5) 24.4 (17.5) 17.3 (9.5) 0.515
Atopic, 𝑛 (%) 36 (52) 8 (28) 12 (55) 0.057
More than 2 chest infections reported in last year, 𝑛 (%) 18 (29) 0 (0) 0 (0)∗ 0.005
SF-36 physical 33.2 (27.1, 42.6) 53.1 (50.1, 56.2)∗ 54.8 (52.9, 57.8)∗ <0.001
SF-36 mental 52.0 (38.1, 59.4) 57.5 (55.5, 60.5)∗ 55.6 (54.4, 57.0)∗ <0.001
Bronchodilator response %, 9.6 (4.1, 15.3) 4.5 (2.4, 6.9)∗ 4.2 (2.6, 5.9)∗ <0.001
Bronchodilator response, 𝑛 (%) 11 (16) 1 (3) 1 (5) 0.127
FEV1% predicted, mean (SD) 52.1 (15.4) 102.8 (16.4)
∗ 108.7 (12.3)∗ <0.001
FEV1/FVC%, mean (SD) 52.2 (11.5) 77.5 (4.1)
∗ 84.8 (5.7)∗ <0.001
KCO% predicted, mean (SD) 53.6 (23.8) 81.1 (10.8)∗ 86.7 (9.9)∗† <0.001
∗
𝑃 < 0.05 versus COPD; †𝑃 < 0.05 versus older healthy control.
SF-36: a short form health survey of 36 questions generic measure of quality of life.
Table 2: Airway inflammation data. All data are median (q1, q3) unless stated.
COPD Older healthy control Younger healthy control 𝑃
Number of patients where sputum was induced, 𝑛 (%) 64 (93) 28 (97) 22 (100) 0.529
Number of patients with adequate sputum used in
analysis, 𝑛 (%) 58 (90) 26 (93) 16 (73) 0.096
Total cell count, ×106/mLa 4.3 (1.7, 6.7), 𝑛 = 51 2.3 (1.4, 3.8), 𝑛 = 23 1.7 (1.1, 3.2)∗, 𝑛 = 15 0.005
Viability, % 81 (67, 93) 79 (67, 89) 67 (59, 76)∗ 0.015
Neutrophils, % 65.0 (43.0, 82.5) 39.6 (27.8, 60.0)∗ 10.8 (7.8, 28.4)∗† <0.001
Neutrophils, 104/mL 244 (78.4, 599) 79.2 (33.1, 227)∗ 22.2 (6.8, 41.6)∗† <0.001
Eosinophils, % 1.0 (0.3, 2.8) 0.3 (0.0, 0.5)∗ 0.1 (0.0, 0.4)∗ <0.001
Eosinophils, ×104/mL 5.1 (0.8, 16.7) 0.6 (0.0, 1.6)∗ 0.0 (0.0, 0.6)∗ <0.001
Macrophages, % 28.4 (12.5, 47.5) 49.1 (34.8, 68.8)∗ 81.3 (64.6, 89.5)∗ <0.001
Macrophages, ×104/mL 78.0 (48.6, 139.5) 117.0 (69.1, 161.3) 137.3 (57.5, 194.1) 0.144
Lymphocytes, % 0.3 (0.0, 0.8) 0.8 (0.0, 1.8)∗ 1.0 (0.0, 1.9) 0.019
Lymphocytes, ×104/mL 0.4 (0.0, 1.7) 1.8 (0.0, 4.2) 1.4 (0.0, 5.1) 0.087
Columnar epithelial cells, % 1.6 (0.5, 2.5) 1.2 (0.3, 2.3) 2.9 (0.4, 6.5) 0.557
Columnar epithelial cells, ×104/mL 5.6 (1.6, 10.4) 2.3 (0.5, 9.8) 4.5 (0.2, 21.1) 0.461
Squamous cells, % 3.5 (1.2, 8.9) 3.6 (2.2, 7.6) 6.7 (3.4, 13.4) 0.135
∗
𝑃 < 0.05 versus COPD; †𝑃 < 0.05 versus older healthy control.
aWhen sputum volume was small, a cell smear was prepared and total cell count and viability data were not collected.
3.3. Effect of Smoking onNeutrophilic Inflammation and Innate
Immune Mediators. To examine the effect of prior smoking
we compared never-smoking controls without COPD (𝑛 =
27) to exsmoking controls without COPD (𝑛 = 15).
The exsmoking controls had significant smoking expo-
surewith 17 (1.5, 45) pack-years, but had a normal FEV
1
(102%
versus 107%, 𝑃 = 0.385) and KCO% predicted (84% versus
82%, 𝑃 = 0.605). They had quit smoking on average 25 years
ago (SD 18, range 0.9–47.2) were older and more likely to be
male (70% versus 39%, 𝑃 = 0.033).
Prior smoking was associated with elevated numbers
of neutrophils (Figure 2(a)) and concentrations of proteases
(MMP-9 and NE; Figures 2(c) and 2(d)). Although higher,
the levels of CXCL8 (Figure 2(b)) in sputum supernatant
from exsmokers were not statistically different (𝑃 = 0.094)
compared with never smokers. There were no effects of
smoking on sputum TLR2 gene expression (Figure 2(e)),
soluble TLR2 levels (Figure 2(f)), or TLR4 gene expression
(never smokers: 0.11 (0.0, 0.12) versus exsmokers: 0.13 (0.10,
0.17); 𝑃 = 0.172).
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Figure 1: Analysis of the effect of age onmarkers of neutrophilic inflammation.This analysis used healthy never-smoking controls comparing
younger (<55 years of age) with older (>55 years of age) controls. (a) Neutrophil number ×104/mL, (b) CXCL8 protein ng/mL, (c) MMP-9
protein ng/mL, (d) NE protein ng/mL, (e) TLR2 gene expression, and (f) soluble TLR2 ng/mL.
3.4. Association between COPD and Neutrophilic Inflamma-
tion and Innate Immune Mediators. Next we examined the
influence of COPD by comparing older healthy controls
without COPD to those participants with COPD. We found
increased neutrophils (Figure 3(a)) andCXCL8 (Figure 3(b)),
MMP-9, and NE levels (Figures 3(c) and 3(d)) in the group
with fixed airflow obstruction. While higher in patients with
COPD, TLR2 gene expression (Figure 3(e)) and soluble TLR2
(Figure 3(f)) levels were not statistically elevated compared
to healthy controls. There was no difference in sputum TLR4
gene expression between participants with COPD (0.15 (0.12,
0.20), compared with older controls (0.14 (0.10, 0.17, 𝑃 =
0.203).
Both mRNA and soluble levels of TLR2 in patients with
COPD were significantly associated with sputum levels of
CXCL8 mRNA (𝑟 = 0.495, 𝑃 < 0.001, 𝑁 = 41) and protein
(𝑟 = 0.614, 𝑃 < 0.001, 𝑁 = 52), MMP-9 mRNA (𝑟 = 0.377,
𝑃 = 0.0016, 𝑁 = 41) and protein (𝑟 = 0.493, 𝑃 < 0.001,
𝑁 = 51), and NE mRNA (𝑟 = 0.518, 𝑃 < 0.001,𝑁 = 39) and
protein (𝑟 = 0.351, 𝑃 < 0.001, 𝑁 = 49).





































































































































Figure 2: Analysis of the effect of smoking on markers of neutrophilic airway inflammation. This analysis used healthy controls, comparing
never smokers with exsmokers. (a) Neutrophil number ×104/mL, (b) CXCL8 protein ng/mL, (c) MMP-9 protein ng/mL, (d) NE protein
ng/mL, (e) TLR2 gene expression, and (f) soluble TLR2 ng/mL.
We then compared clinical and inflammatory outcomes
in patients withmoderate and severe COPD.While similar in
terms of age, gender, and smoking histories (Table 3), patients
with severe COPD had a significantly higher proportion
of sputum neutrophils (Figure 4(a)) as well as increased
gene expression (Figure 4(e)) and levels of soluble TLR2
(Figure 4(f)).
3.5. TLR2 Gene Expression and Total MMP-9 Levels Are
Independent Determinants of Neutrophilic Bronchitis. Amul-
tiple regression analysis was performed to further explore
the determinants of neutrophilic bronchitis in all partic-
ipants and to adjust for other determinants such as age,
gender, and corticosteroid dose. Sputum neutrophils were
significantly and independently associated with TLR2 gene
expression and sputum MMP-9 levels (Table 4). Smok-
ing history, age, inhaled corticosteroid dose, and airflow
obstruction were not significantly correlated with sputum
neutrophil proportion when adjusted for CXCL8, NE, and
soluble TLR2 levels. The model was both highly signifi-
cant and highly explanatory, with an adjusted 𝑅2 of 59.08,
𝑃 < 0.0001.




































































































































Figure 3: Analysis of the effect of the presence of airflow obstruction onmarkers of neutrophilic inflammation.This analysis compared older
healthy controls with participants with COPD. (a) Neutrophil number ×104/mL, (b) CXCL8 protein ng/mL, (c) MMP-9 protein ng/mL, (d)
NE protein ng/mL, (e) TLR2 gene expression, and (f) soluble TLR2 ng/mL.
3.6. Peripheral Blood Cells Are Responsive to TLR2 Stimula-
tion. We assessed TLR2 activation in peripheral blood gran-
ulocytes and mononuclear cells in 7 participants with COPD
with a median (q1, q3) age of 65 (63, 67) years, 3 were
male, and 4 were exsmokers. The median (q1, q3) FEV
1
%
predicted was 51.4 (40.8, 60.5), and FEV
1
/FVCwas 61.9 (42.9,
68.0). Following TLR2 stimulation of PBMCs from patients
with COPD, both surface and gene expression of TLR2 were
increased (Figures 5(a) and 5(b)). There was a significant
increase in TLR2 gene expression but not surface expression
on peripheral granulocytes (Figures 5(c) and 5(d)).
3.7. Neutrophil Proteases and Innate Inflammatory Cytokines
Are Released Following TLR2 Stimulation of COPD Periph-
eral Blood Cells . Peripheral blood cells were stimulated
with Pam3CysK4 and supernatant examined for release of
inflammatory cytokines and proteases. TLR2 stimulation
resulted in increased release of CXCL8, IL-6, IL-1𝛽, and
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Table 3: Clinical and inflammatory outcomes according to the severity of airflow obstruction in patients with COPD. Data are median (q1,
q3) unless indicated.
Moderate COPD Severe COPD 𝑃
𝑛 34 20
Age, mean (SD) 70.4 (7.3) 69.9 (7.9) 0.844
Sex, male/female 16/28 9/11 0.555
Smoker, never/ex 12/22 3/17 0.096
Pack years 32.3 (17, 46.6) 37.3 (19.5, 53.8) 0.444
FEV1% predicted 65.3 (57.9, 69.8) 43.8 (38.2, 46.8) <0.001
ICS dose 2000 (1000, 2000) 2000 (2000, 2000) 0.183
TLR4 mRNA 0.15 (0.12, 0.18),𝑁 = 26 0.16 (0.11, 0.22),𝑁 = 12 0.648
Table 4: Multivariate linear regression outcomes to determine predictors of sputum neutrophil proportion.
Variable Coefficient SE 𝑃 95% confidence interval
Age, years 0.068 0.232 0.771 −0.400 to 0.537
Sex (male/female) 8.968 6.596 0.181 −4.342 to 22.278
Smoker (ex/never) 2.988 6.994 0.671 −11.123 to 17.103
FEV1/FVC, % −0.130 0.239 0.589 −0.613 to 0.353
Soluble TLR2 ng/mL −0.048 0.137 0.729 −0.324 to 0.228
Log TLR2 gene expression 16.244 4.793 0.002 6.570 to 25.917
Log TLR4 gene expression 12.405 9.104 0.180 −5.968 to 30.778
Log MMP-9 protein 34.523 10.253 0.002 13.831 to 55.215
Log NE 2.122 5.566 0.705 −9.110 to 13.354
Log CXCL8 −3.969 8.292 0.635 −20.703 to 12.765
Dose-inhaled corticosteroids, 𝜇g daily −0.003 0.003 0.369 −0.009 to 0.004
Constant −69.667 46.503 0.142 −163.514 to 24.181
TNF-𝛼 from peripheral blood mononuclear cells (Figures
6(a)–6(d)) and CXCL8, IL-6, and MMP-9 from granulocytes
(Figures 6(e)–6(g)). Release of NE was not altered with
Pam3CysK4 stimulation (Figure 6(h)).
MMP-9 and NE were only assessed in granulocyte cul-
tures’ culture supernatant only as they are predominantly
neutrophil proteases.
4. Discussion
This study evaluated the determinants of the persistent neu-
trophilic bronchitis, that is a characteristic of COPD, and
the role of ageing and smoking, and COPD severity. Ele-
vated TLR2 levels were associated with ageing and more
severe COPD. Sputum neutrophils and total MMP-9 levels
increased with age, prior smoking, and the presence of fixed
airflow obstruction. Gene expression for TLR2 and super-
natant MMP-9 levels were significant independent contrib-
utors to the proportion of sputum neutrophils after adjust-
ment for age, prior smoking, and the presence of airflow
obstruction. The TLR2 receptor was functionally active in
COPDwith stimulation of peripheral blood granulocytes and
mononuclear cells leading to the release of key neutrophil and
innate immune system mediators including MMP-9. These
results implicate a significant role for the innate immune
system in neutrophilic bronchitis in COPD and suggest
activation of TLR2 and subsequent release of MMP-9 may be
critical points in the regulation of neutrophilic bronchitis in
COPD.
Ageing, smoking, and airflow obstruction have each been
linked to airway neutrophilia. A number of studies have
reported similar or increased circulating neutrophil numbers
in the elderly [16], but few have examined airway neutrophils
and associated inflammation in older people. Thomas et
al. reported a significant positive relationship between neu-
trophils and age after examining sputum neutrophils in >60
healthy nonsmoking controls, with older controls having
a neutrophil proportion of 68.5% compared with younger
healthy controls [17]. We extend these findings by demon-
strating age-related increases in TLR2 gene expression, sol-
uble TLR2 levels, and MMP-9 levels. Age has been shown
to have no effect on the expression of TLR2 and -4 on
peripheral blood neutrophils using flow cytometry [18]. In
our examination of induced sputum, we found that TLR2
but not TLR4 gene expression was increased in older healthy
controls compared with younger healthy controls, indicating
that TLR2 expression increases with age. We also observed
higher levels of soluble TLR2 in older nonsmoking controls
compared with younger nonsmoking controls.These changes
could represent airway centric changes in innate immune
receptor expression and function with age, which is sup-
ported by a recent animal study showing increased airway
macrophage TLR2 expression with advanced age [19].






























































































































Figure 4: Analysis of the effect of the severity of airflow obstruction on markers of neutrophilic inflammation. This analysis compared
participants with moderate and severe COPD. (a) Neutrophil number ×104/mL, (b) CXCL8 protein ng/mL, (c) MMP-9 protein ng/mL, (d)
NE protein ng/mL, (e) TLR2 gene expression, and (f) soluble TLR2 ng/mL.
Prior smoking was associated with increased airway
neutrophils and release of MMP-9 and NE. These data
extend previous reports of associations between smoking
and reduced lung function, neutrophilia and increased levels
of CXCL8 in sputum supernatants from younger controls,
[20] and elevated levels of MMP-9 in current smokers com-
pared with nonsmokers [21]. We observed similar effects in
exsmokers suggesting that cigarette smokingmay irreversibly
exaggerate innate immune responses and lead to low grade
neutrophilic inflammation, prior to the clinical expression of
airway disease. Indeed, when active smokers cease smoking,
MMP-9 levels remain unaltered [22]. Alterations in MMP-
9 may serve as an early indicator of smoking-related airway
damage due to elevation in both asymptomatic exsmokers
(shown here) and current smokers [23], and further work
is required to determine its suitability as a biomarker of
smoking-related airway disease.
Neutrophilic bronchitis is also a feature of other chronic
airway diseases such as bronchiectasis [5], allergic bron-
chopulmonary aspergillosis [24], and the neutrophilic sub-
type of asthma [25]. In these diseases there are increased
levels of mediators of neutrophilic inflammation (CXCL8),


















































Figure 5: TLR2 surface and gene expression following TLR2 stimulation using Pam3CysK4: (a) mononuclear cells TLR2 surface expression,
(b) mononuclear cells TLR2 gene expression, (c) granulocyte TLR2 surface expression, and (d) granulocyte TLR2 gene expression.
neutrophil elastase (NE), and matrix metalloproteinase-
(MMP-) 9 and strong associations observed between the
expression of these mediators and elevated numbers of spu-
tum neutrophils. This suggests there may be common mech-
anisms contributing to persistent neutrophilia in airway dis-
ease and COPD [26–28], and in this study we have observed
similar increases in mediators of neutrophilic inflammation
and associations between mediators and sputum neutrophil
proportion. In cell culture systems, neutrophils releaseMMP-
9 in the presence of CXCL8, and NE can induce CXCL8,
which indicates that neutrophils can perpetuate their own
accumulation and activation [29, 30].
A likely explanation of this specific enhancement of
neutrophilic inflammation may lie in the cumulative effect of
the exposures experienced by participants. These exposures
included not only tobacco smoke, but also likely other
pollutants or past infections all of which can induce epi-
genetic alterations, and these possibilities require further
investigations [31].The hypothesis of “multiple inflammatory
hits” initially proposed by Pavord et al., in severe refractory
asthma [32], may explain the changes in disease parameters
observed in this study, with those with COPD having more
inflammatory “hits” than exsmoking or nonsmoking con-
trols.
The COPD population in this study was primarily treated
with maintenance inhaled corticosteroids which is common
and recommended in COPD. A small proportion of those
with COPD showed a response to bronchodilator on the day
of assessment, and around 25% had a sputum eosinophil
proportion of more than 3% which suggests further manage-
mentwith inhaled corticosteroids or an assessment of therapy
may be considered.While these are characteristics of patients
with asthma, asthma is also a significant risk factor for the
development of COPD; therefore this is not a surprising
result. Approximately half of the COPD population studied
were atopic. In a recent study the presence of atopy in COPD
was associated with increased respiratory symptoms and
more likely to have a resolution of symptoms on treatment


























































































































Figure 6: Release of inflammatory mediators from mononuclear cells and granulocytes isolated from patients with COPD. (a) CXCL8
release from mononuclear cells, (b) IL-6 release from mononuclear cells, (c) IL-1𝛽 release from mononuclear cells, (d) TNF-𝛼 release from
mononuclear cells, (e) CXCL8 release from granulocytes, (f) IL-6 release from granulocytes, (g) MMP-9 release from granulocytes, and (h)
NE release from granulocytes.
with budesonide [33], and the presence of atopy is considered
to be a “minor” criteria for the definition of asthma/COPD
overlap [34].
Innate immune responses are rapidly activated by patho-
gen-associated molecular patterns, which are highly con-
served microbial factors. They are recognised by pattern
recognition receptors such as toll-like receptors (TLRs),
CD14, and collectins [35]. TLR activation triggers signaling
cascades that lead to the activation and nuclear translocation
of NF-𝜅B resulting in proinflammatory cytokine responses
including TNF-𝛼, IL-8, and IL-1𝛽 [36, 37].
Stimulation of TLR2 induced increased TLR2 gene ex-
pression in peripheral blood granulocytes and increased
release of the neutrophil chemoattractant CXCL8 and the
neutrophil protease MMP-9, while stimulation of peripheral
blood monocytic cells leads to increased gene and surface
expression of TLR2 as well as the release of CXCL8 and innate
cytokines TNF-𝛼 and IL-1𝛽. It is a limitation to this study that
we were not able to show TLR2 activation of airway cells. We
have previously reported that sputum cells are refractory to
stimulation with LPS which may be due to the cells already
being maximally activated, whether this occurs while in the
airway or as a result of the sputum induction process which
requires further study [38].
We extend the findings of Von Scheele et al. [8] to show
that soluble levels of TLR2 are further elevated in severe
compared with moderate COPD and that, in participants
with COPD, soluble TLR2 levels are closely associated
with sputum levels of CXCL8, which is the key neutrophil
chemoattractant. The levels of soluble TLR2 correlated with
12 Mediators of Inflammation
increased levels of MMP-9 and NE, and it is possible that
these proteases may cleave off TLR2 from cells increasing
the levels of the soluble form and influence their ability to
respond to agonists of the receptor. Stimulation with the
TLR2 agonist Pam3CysK4 has been shown to induce MMP-
9 production in other cell types such as THP-1 cells and
keratinocytes [39]; our work extends these observations to
show that stimulation of granulocytes with Pam3CysK4 also
induces projection of MMP-9 and suggests the potential
of TLR2 to influence tissue remodeling and repair in the
airways. Corticosteroids have also been shown to enhance the
TLR2 response in airway epithelial cells [40–42], and thus it
is important that further research is undertaken to elucidate
the effect of steroids on TLR2 expression and responsiveness
in COPD.
Animal studies also support key roles for TLR2 as a
determinant of airway neutrophilia. TLR2 (but not TLR4)
expression is increased on lung macrophages in a mouse
model of infection-induced neutrophilic allergic airway dis-
ease [43]. In a model of organic dust-induced airway inflam-
mation, TLR2 knockout mice had significantly lower airway
neutrophils, IL-6, TNF-𝛼, and CXCL-1 (mouse homolog of
CXCL8) compared with wild-type controls suggesting that
airway inflammation is dependent on TLR2 [44]. This is
the same pattern of cytokines we observed following TLR2
stimulation in peripheral blood cells from patients with
COPD and in induced sputum samples from patients with
COPD.
In conclusion, we have shown that airway neutrophilia
and MMP-9 are enhanced with age, smoking, and the pre-
sence of COPD. Sputum TLR2 gene expression was signifi-
cantly increased with age but not prior smoking; however it
was enhanced in COPD and increased with COPD severity.
TLR2 gene expression and MMP-9 levels were significant
independent predictors of neutrophils in sputum, and the
receptor was shown to be functional and could be activated to
induce the release of MMP-9 and CXCL8 from granulocytes
aswell as innate cytokines IL-1𝛽 andTNF-𝛼 frommonocytes.
These results extend our understanding of the role of the
innate immune response in inducing neutrophilia in airways
disease and provide new insights for the development of
effective therapies.
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